Oncotarget

Clinical Research Papers:

A phase I study of indoximod in patients with advanced malignancies

Hatem H. Soliman _, Susan E. Minton, Hyo Sook Han, Roohi Ismail-Khan, Anthony Neuger, Fatema Khambati, David Noyes, Richard Lush, Alberto A. Chiappori, John D. Roberts, Charles Link, Nicholas N. Vahanian, Mario Mautino, Howard Streicher, Daniel M. Sullivan and Scott J. Antonia

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:22928-22938. https://doi.org/10.18632/oncotarget.8216

Metrics: PDF 2813 views  |   HTML 4159 views  |   ?  


Abstract

Hatem H. Soliman1, Susan E. Minton1, Hyo Sook Han1, Roohi Ismail-Khan1, Anthony Neuger1, Fatema Khambati1, David Noyes1, Richard Lush1, Alberto A. Chiappori1, John D. Roberts2, Charles Link3, Nicholas N. Vahanian3, Mario Mautino3, Howard Streicher4, Daniel M. Sullivan1 and Scott J. Antonia1

1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

2 Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA

3 NewLink Genetics Inc., Ames, Iowa, USA

4 Cancer Therapeutics Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA

Correspondence to:

Hatem H. Soliman, email:

Keywords: indoleamine 2,3 dioxygenase, 1-methyl-D-tryptophan, indoximod, immunomodulator

Received: February 11, 2016 Accepted: March 10, 2016 Published: March 20, 2016

Abstract

Purpose: Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharmacokinetics, and immune correlates.

Experimental Design: Our 3+3 phase I trial comprised 10 dose levels (200, 300, 400, 600, and 800 mg once/day; 600, 800, 1200, 1600, and 2000 mg twice/day). Inclusion criteria were measurable metastatic solid malignancy, age ≥18 years, and adequate organ/marrow function. Exclusion criteria were chemotherapy ≤ 3 weeks prior, untreated brain metastases, autoimmune disease, or malabsorption.

Results: In 48 patients, MTD was not reached at 2000 mg twice/day. At 200 mg once/day, 3 patients previously treated with checkpoint inhibitors developed hypophysitis. Five patients showed stable disease >6 months. Indoximod plasma AUC and Cmax plateaued above 1200mg. Cmax (~12 μM at 2000 mg twice/day) occurred at 2.9 hours, and half-life was 10.5 hours. C reactive protein (CRP) levels increased across multiple dose levels.

Conclusions: Indoximod was safe at doses up to 2000 mg orally twice/day. Best response was stable disease >6 months in 5 patients. Induction of hypophysitis, increased tumor antigen autoantibodies and CRP levels were observed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8216